Pioneering the technology behind groundbreaking antibody therapy treatments.
True Human™ monoclonal antibodies are derived from those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. XBiotech believes that naturally occurring monoclonal antibodies have the potential to be safer, more effective and faster to develop than their non-naturally occurring counterparts. The Company is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure that reduces the cost and time to launch new product candidates. The Company’s discovery and manufacturing technology makes XBiotech uniquely suited to rapidly identify neutralizing antibodies from humans and to quickly manufacture these product candidates for human use.
TECHNOLOGIES
XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technology enables the rapid development of antibody therapies directly from human blood samples that can be used to neutralize infectious disease. Our True Human antibody therapies allow us to recapitulate key components of the natural immunity obtained from an immune blood donor. We combine this discovery program with a novel manufacturing platform to facilitate rapid commercial-scale production. We believe our capabilities are unparalleled in the pharmaceutical industry to discover and create novel, effective treatments for infectious disease, including rapidly addressing infectious disease outbreaks.
facilities
XBiotech has a fully integrated research and manufacturing center and a separate infectious disease research laboratory at its campus headquarters in Austin, Texas. The Company is now expanding its manufacturing center, with additional inventory area and personnel offices to accommodate greater output, a larger workforce, and around-the-clock manufacturing operations. A new 30,000 square foot infectious disease R&D center is also planned for construction on the campus adjacent to the existing R&D and manufacturing center.
validation of true Human™
On December 30, 2019, XBiotech sold an IL-1a blocking True Human™ antibody that had been used successfully in a number of clinical trials. The sale generated $750 million in upfront cash and up to $600 million in potential milestone payments. As part of this, XBiotech agreed not to develop or market anti-IL-1a antibody treatments for dermatological diseases only. XBiotech retains the right to pursue the development of True Human™ antibodies targeting IL-1a for all areas of medicine outside of dermatology. Due to the speed and effectiveness of XBiotech’s True Human™ antibody discovery technology, the Company has already identified new IL-1a-targeting product candidates to bring into the clinic. While XBiotech previously focused on a single True Human™ antibody targeting IL-1a, the Company now plans to develop multiple product candidates, each of which will target IL-1a in a specific area of medicine.
history
core beliefs
The Hippocratic Oath that medicine "should never do harm" is a cornerstone to how we approach drug development. This includes the belief that cutting-edge medicine should work in a targeted way to make patients feel better, not worse. We believe this principle should continue to shape the future of medicine.
